Walder Wyss advises Veraxa on NASDAQ listing

Walder Wyss advised Veraxa Biotech (Veraxa) on its business combination with Voyager Acquisition Corp., culminating in a listing on the NASDAQ Stock Market under the ticker symbols VRXA and VRXAW.

The transaction strengthened Veraxa’s financial position through a USD 27.5 million senior secured note financing and a share purchase agreement for up to USD 50 million. The proceeds are earmarked to advance Veraxa’s oncology pipeline, which is built on its proprietary BiTAC platform, with the aim of progressing toward clinical development and industry partnerships in antibody-based cancer therapeutics.

Walder Wyss team

The Walder Wyss team was led by partner Marius Breier (tax, pictured left) and partner Thiemo Sturny (corporate/M&A, pictured right). The broader team included senior associate Martina Madonna-Quadri (corporate/M&A), counsel Stefan Walder (corporate/M&A), senior associate Manu Ferro (banking & finance), managing associate Dimitrios Berger (corporate/M&A), managing associate Christian A. Schmid (corporate/M&A), partner Maurus Winzap (tax), and associate Nicolas Bopp (tax), all advising on the relevant Swiss tax and legal aspects of the transaction and the listing.